InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,620.85
(
0.42%
)
US TECH 100
19,310.40
(
0.52%
)
Dow Jones
40,890.49
(
0.14%
)
Brent Oil
75.69
(
-1.39%
)
Bitcoin
61,180.00
(
3.68%
)
Post# of 252939
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

zigzagman

Send PM Follow Ignore
Followers 646
Posts 144549
Boards Moderated 1
Alias Born 05/19/2007

zigzagman

Re: DewDiligence post# 86993

Sunday, 12/06/2009 1:40:50 PM

Sunday, December 06, 2009 1:40:50 PM

Post# of 252939
Phase III Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin’s Lymphoma (EXTEND): Results From the Treatment and Follow-up Periods:

http://ash.confex.com/ash/2009/webprogram/Paper25134.html

This information is a bit too technical for me...Did it pass Phase III with flying colors?...Any comments anyone?...TIA

If you missed yesterday's Analyst Conference, here's a link to it:

http://investors.celltherapeutics.com/phoenix.zhtml?c=92775&p=irol-EventDetails&EventId=2562799

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up